This conference will bring together leading neuroscientists from academia and industry involved in genomics, proteomics, diagnostics, imaging, drug development and regulatory affairs.

The discovery and validation of biomarkers across neuroscience is an important challenge for early diagnosis of disease and for the development of therapeutics. Methodological and regulatory aspects of biomarker identification and qualification across a wide spectrum of neurodegenerative diseases will be discussed. There will also be a series of break-out sessions for in-depth discussion on cognitive and functional biomarkers, and the analytical and clinical standards required in ‘big data’ projects.

This meeting is an opportunity for scientists from academia and the commercial sector to discuss the state of the art in biomarkers, and will aid future investment decisions in both sectors. We welcome abstracts relevant to the main themes of the meeting. Several oral presentations will be chosen from the abstracts submitted.